Advertisement

Rheumatology International

, Volume 32, Issue 1, pp 1–3 | Cite as

Successful use of Etanercept for the treatment of Reiter’s syndrome: a case report and review of the literature

  • Amr EdreesEmail author
Review Article

Abstract

The treatment of severe and refractory cases of reactive arthritis is not well defined. There is a limited data about the use of tumor necrosis factor-α (TNF-α) blockers in reactive arthritis. Herein is a description of a patient with severe case of Chlamydia trachomatis-related reactive arthritis that was refractory to nonsteroidal anti-inflammatory drugs, sulfasalazine, prednisone, and methotrexate and was successfully treated with etanercept.

Keywords

Reactive arthritis Tumor necrosis factor-α (TNF-α) blockers Etanercept 

References

  1. 1.
    Carter JD, Hudson AP (2009) Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am 35(1):21–44PubMedCrossRefGoogle Scholar
  2. 2.
    Ahvonen P, Sievers K, Aho K (1969) Arthritis associated with yersinia enterocolitica infection. Acta Rheumatol Scand 15:232–253PubMedGoogle Scholar
  3. 3.
    Braun J, Kingsley G, van der Heijde D, Sieper J (2000) On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th international workshop on reactive arthritis, Berlin, Germany, July 3–6, 1999. J Rheumatol 27(9):2185–2192Google Scholar
  4. 4.
    Kvien TK, Glennas A, Melby K, Granfors K, Andrup O, Karstensen B, Thoen JE (1994) Reactive arthritis: incidence, triggering agents and clinical presentation. J Rheumatol 21(1):115–122PubMedGoogle Scholar
  5. 5.
    Amor B, Santos RS, Nahal R, Listrat V, Dougados M (1994) Predictive factors for the long term outcome of spondyloarthropathies. J Rheumatol 21(10):1883–1887PubMedGoogle Scholar
  6. 6.
    Egsmose C, Hansen TM, Andersen LS, Beier JM, Christensen L, Ejstrup L, Peters ND, van der Heijde DM (1997) Limited effect of sulphasalazine treatment in reactive arthritis. A randomized double blind placebo controlled trial. Ann Rheum Dis 56(1):32–36PubMedCrossRefGoogle Scholar
  7. 7.
    Carter JD, Espinoza LR, Inman RD et al (2010) Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 62(5):1298–1307PubMedGoogle Scholar
  8. 8.
    Putschky N, Pott HG, Kuipers JG et al (2006) Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. Ann Rheum Dis 65(11):1521–1524PubMedCrossRefGoogle Scholar
  9. 9.
    Gaylis N (2003) Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. J Rheumatol 30(2):407–411PubMedGoogle Scholar
  10. 10.
    Gill H, Majithia V (2008) Successful use of infliximab in the treatment of Reiter’s syndrome: a case report and discussion. Clin Rheumatol 27(1):121–123PubMedCrossRefGoogle Scholar
  11. 11.
    Schafranski MD (2010) Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection. Rheumatol Int 30:679–680PubMedCrossRefGoogle Scholar
  12. 12.
    Flagg SD, Meador R, Hsia E, Kitumnuaypong T, Schumacher HR Jr (2005) Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 53(4):613–617PubMedCrossRefGoogle Scholar
  13. 13.
    Rihl M, Gu J, Baeten D, Märker-Hermann E, Goodall JC, Gaston JS, Kuipers JG, Zeidler H, Yu DT (2004) Alpha beta but not gamma delta T cell clones in synovial fluids of patients with reactive arthritis show active transcription of tumor necrosis factor alpha and interferon gamma. Ann Rheum Dis 63(12):1673–1676Google Scholar
  14. 14.
    Thiel A, Wu P, Lauster R, Braun J, Radbruch A, Sieper J (2000) Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis Rheum 43(12):2834–2842PubMedCrossRefGoogle Scholar
  15. 15.
    Kotake S, Schumacher HR Jr, Yarboro CH et al (1997) In vivo gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis. Proc Assoc Am Physicians 109(3):286–301PubMedGoogle Scholar
  16. 16.
    Shemer-Avni Y, Wallach D, Sarov I (1988) Inhibition of Chlamydia trachomatis growth by recombinant tumor necrosis factor. Infect Immun 56(9):2503–2506PubMedGoogle Scholar
  17. 17.
    Huppertz HI, Heesemann J (1999) Effect of cytokines on invasion and survival of Yersinia in primary human fibroblasts. Med Microbiol Immunol 187(3):157–164PubMedCrossRefGoogle Scholar
  18. 18.
    Braun J, Yin Z, Spiller I, Siegert S et al (1999) Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 42(10):2039–2044PubMedCrossRefGoogle Scholar
  19. 19.
    Meador R, Hsia E, Kitumnuaypong T, Schumacher HR (2002) TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin Exp Rheumatol 20(6 Suppl 28):S130–S134PubMedGoogle Scholar
  20. 20.
    Kvien TK, Gaston JS, Bardin T, Butrimiene I, Dijkmans BA, Leirisalo-Repo M (2004) Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis 63(9):1113–1119PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.University of Missouri-Kansas CityKansas CityUSA

Personalised recommendations